Clinical trials: Stroke, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Stroke
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Acute Ischemic Stroke
Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke
The HOPE-MeVO study aims to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke due to medium vessel occlusion presenting 4.5 to 24 hours after stroke…
- Trial name
- HOPE-MeVO (NCT07776873)
- Testing
- Recombinant Human Prourokinase for Injection (rhPro-UK), Standard medical treatment (SMT)
- Where
- China
- Volunteers
- 616 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Acute Ischemic Stroke
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
The primary objective is to establish the efficacy of intra-arterial (IA) mechanical thrombectomy (MT) with extracranial proximal carotid artery acute stenting versus non-stenting approaches in patients with acute ischemic stroke…
- Trial name
- PICASSO (NCT05611242)
- Testing
- MT+CAS with IV-AP, MT+CAS with PO-AP, MT+CAT with PO-AP
- Where
- 60 sites in United States
- Volunteers
- 404 people
- Sponsor
- Mercy Health Ohio
Acute Ischemic Stroke
A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Duration of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Acute ischemic stroke is a leading cause of disability and mortality among dults in China. Although intravenous thrombolysis serves as first-line reperfusion therapy, nearly half of patients fail to achieve vascular…
- Trial name
- INSTANT-2 (NCT07842185)
- Testing
- Tirofiban Injection, No Interventions
- Where
- 10 sites in China
- Volunteers
- 1,482 people
- Sponsor
- Xinqiao Hospital of Chongqing
Acute Stroke, Ischemic Stroke
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and…
- Conditions
- Acute Stroke, Ischemic Stroke, Stroke
- Trial name
- ReMEDy2 (NCT05065216)
- Testing
- Recombinant human tissue kallikrein
- Where
- 86 sites in United States, Belgium and 8 more
- Volunteers
- 728 people
- Sponsor
- DiaMedica Therapeutics Inc
Acute Ischemic Stroke
A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke
The goal of this clinical trial is to learn if AB126, an investigational treatment made from neural exosomes, is safe and well tolerated when given to adults with moderate to severe acute ischemic stroke (AIS) who have undergone…
- Trial name
- NEXIS (NCT07813130)
- Testing
- AB126 Neural Exosomes Intravenous Injection
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aruna Bio, Inc.
Ischemic Stroke
Safety and Preliminary Efficacy of NXL-001 in Patients With Ischemic Stroke
This is a single-arm, open-label, single center, dose-escalation exploratory clinical study to evaluate the safety and tolerability of a single intracerebral injection of NXL-001, a NeuroD1 base gene therapy, in patients with…
- Trial name
- NXL-001 (NCT06761183)
- Testing
- intracerebral stereotactic injection of NXL-001
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Tiantan Hospital
Acute Ischemic Stroke
Safety and Efficacy of J147 in Acute Ischemic Stroke
The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients.
- Trial name
- JUMPSTART (NCT07430917)
- Testing
- J147 Emulsion for Injection
- Where
- 5 sites in United States
- Volunteers
- 196 people
- Sponsor
- Abrexa Pharmaceuticals, Inc.
Acute Ischemic Stroke
Intra-arterial Selective Hypothermic Magnesium Sulfate Infusion in Combination With Endovascular Thrombectomy in Acute Ischemic Stroke
The primary objective of this study is to estimate the safety and effectiveness of selective intra-arterial hypothermic magnesium sulfate infusion after endovascular thrombectomy in patients with acute ischemic stroke.
- Trial name
- ICE-MAG (NCT07163299)
- Testing
- Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml)., Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (500 ml)., Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (650 ml).
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Capital Medical University
Intracerebral Hemorrhage, Stroke
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV…
- Conditions
- Intracerebral Hemorrhage, Stroke, Hypertension
- Trial name
- CLUTCH (NCT06402968)
- Testing
- Clevidipine Injection, Alternate IV Antihypertensive Regimen
- Where
- 20 sites in United States
- Volunteers
- 1,018 people
- Sponsor
- Zeenat Qureshi Stroke Institute
Acute Ischemic Stroke AIS
A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS
This is a Phase IIa clinical trial with a three-arm design that utilizes randomization, double-blinding, and placebo control. The primary objective of this study is to evaluate the efficacy of single and multiple intravenous…
- Trial name
- NCT07084012
- Testing
- hUC-MSCs treatment (high dose), hUC-MSCs treatment (low dose)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Wingor Biotechnology Co., Ltd.
Acute Coronary Syndromes (ACS), Recent Myocardial Infarction
The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants
CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®， but with different active metabolite conversion routes.
- Conditions
- Acute Coronary Syndromes (ACS), Recent Myocardial Infarction, Recent Stroke, Peripheral Arterial Disease
- Trial name
- NCT07619885
- Testing
- CG-0255 Besylate for Injection, CG-0255 Besylate Capsule, Clopidogrel
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Shanghai CureGene Pharmaceutical Co., Ltd.
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Acute Ischemic Stroke, AIS
A Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells for Acute Ischemic Stroke
Study Methods: The trial consists of two phases, both including a placebo control. Phase Ia (single-dose, dose-escalation): Three dose groups (low, medium, high) are set.
- Trial name
- NCT07628933
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells Injection
- Where
- China
- Volunteers
- 35 people
- Sponsor
- BOE Technology Group Co., Ltd.
Ischemic Stroke, Acute, Cerebrovascular Disorders
Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke
Multicentre, prospective, Multi-arm Multi-stage (MAMS) seamless phase 2b/3 interventional randomized placebo-controlled double-blinded parallel-assignment (2 arms with 1:1 randomization) efficacy and safety trial to test…
- Conditions
- Ischemic Stroke, Acute, Cerebrovascular Disorders, Brain Disorder, Central Nervous System Diseases
- Trial name
- NCT05892510
- Testing
- Intra-arterial tenecteplase injection at the completion of thrombectomy
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 462 people
- Sponsor
- University of Melbourne
Ischemic Stroke
Modulation of Cerebral Ischemia by Albumin
A single-center, open-label, randomized, placebo-controlled, prospective phase II clinical trial to investigate the efficacy of low-dose albumin in patients with ischemic stroke with an indication for vasographic intervention.
- Trial name
- MOZEG (NCT07415655)
- Testing
- Albumin infusion
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital Hradec Kralove
Acute Ischemic Stroke, Cerebral Infarction
Safely Quenching Complement in Stroke Survivors
This study will include adults (ages 18-80) who have had a stroke caused by a large blood clot blocking blood flow in the brain.
- Trial name
- SUCCESS (NCT07495722)
- Testing
- Pegcetacoplan Injection [Empaveli]
- Volunteers
- 20 people
- Sponsor
- Columbia University
Ischemic Stroke, Acute, Active Malignancies
A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy
This multicenter randomized controlled trial aims to evaluate the efficacy and safety of edaravone dexborneol injection in patients with acute ischemic stroke (AIS) complicated by active malignancies.
- Trial name
- PRECISE AM (NCT07091994)
- Testing
- edaravone dexborneol injection, Standard therapeutic protocol
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Stroke, Acute Ischemic Stroke
The Feasibility and Safety of RK-4 Injection Bypassing Blood-brain Barrier in the Treatment of Acute Large Hemispheric Infarction Using Intracalvariosseous Injection Device
A pilot study confirmed the feasibility and safety of neuroprotectant RK-4 intracalvariosseous(ICO) injection in patients with malignant middle cerebral artery infarction (mMCAI), showing a trend in improving 90-day functional…
- Conditions
- Stroke, Acute Ischemic Stroke, Blood-Brain Barrier
- Trial name
- SOLUTION-ICD (NCT07514949)
- Testing
- RK-4 ICO injection, Conventional treatment
- Where
- China
- Volunteers
- 6 people
- Sponsor
- yilong Wang
Ischemic Stroke
CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in Stroke - HIBISCUS-STROKE II
Ischemic stroke is the first cause of acquired disability of the adult, the second cause of dementia and the third cause of death in the industrialized countries, what constitutes à major public health issue.
- Trial name
- HIBI STROKE II (NCT05263804)
- Testing
- Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection, Cardiac MRI with gadolinium injection - Ancillary Study
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Hospices Civils de Lyon
Spasticity as Sequela of Stroke
Phenol and Botulinum Toxin vs Botulinum Toxin Alone for Post-Stroke Upper-Limb Spasticity
This study aims to evaluate the efficacy of a combined treatment approach for post-stroke upper limb spasticity using phenol neurolysis and botulinum toxin (BoNT).
- Trial name
- NCT07440173
- Testing
- phenol neurolysis, Botulinum Toxin - A injections
- Volunteers
- 60 people
- Sponsor
- Assiut University